OpGen (NASDAQ:OPGN) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research report released on Tuesday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of OpGen stock opened at $1.83 on Tuesday. The business has a fifty day simple moving average of $2.04 and a 200-day simple moving average of $3.39. OpGen has a fifty-two week low of $1.61 and a fifty-two week high of $38.40.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp bought a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen as of its most recent SEC filing. Institutional investors and hedge funds own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.